drugset
drugset / Trial / NCT00071084

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

NCT00071084 ↗

Phase 2 Completed 22 enrolled Genmab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL). Almost all participants who are affected by late stage CTCL have many cancerous cells which bear a receptor called CD4. HuMax-CD4 is an investigational drug directed against this receptor. There is no placebo in this trial; all participants will be treated with HuMax-CD4. The response rates, duration of responses, relief of symptoms, and safety profile of HuMax-CD4 will be evaluated during this trial.

Timeline

Start
2003-05-27
Primary completion
2004-06-29
Completion
2004-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanolimumab Monoclonal antibody 280 mg Subcutaneous
Subject Zanolimumab Monoclonal antibody 980 mg Subcutaneous

Indications

primary cutaneous T-cell lymphoma